Survival in Systemic Sclerosis-Pulmonary Arterial Hypertension by Serum Autoantibody Status in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Registry

Documenti analoghi

• Long-Term Outcomes in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS)
  di: Kolstad, Kathleen D., et al.
  Pubblicazione: (2018)
• Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): Baseline Characteristics and Description of Study Population
  di: Hinchcliff, Monique, et al.
  Pubblicazione: (2011)
• Baseline Characteristics and Follow up in Patients with Normal Hemodynamics vs. Borderline Mean Pulmonary Arterial Pressure in Systemic Sclerosis — Results from the PHAROS Registry
  di: Bae, Sangmee, et al.
  Pubblicazione: (2012)
• Changes in hemodynamic classification over time are common in systemic sclerosis-associated pulmonary hypertension: insights from the PHAROS cohort
  di: Lammi, Matthew R., et al.
  Pubblicazione: (2018)
• Clinical characteristics and survival of systemic sclerosis patients with pulmonary hypertension and elevated wedge pressure: Observations from the PHAROS cohort
  di: Lammi, Matthew R., et al.
  Pubblicazione: (2017)